You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME/CE Test

Linking Inaugural Skin Manifestations With BPDCN: Clinical Pearls for Identification and Management

  1. In a clinical trial with CD123-targeted IMGN632, what is the overall response rate (ORR) in patients with relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with no more than 3 prior lines of therapy?
    14%
    29%
    44%
    59%